MCS110
Sponsors
Novartis Pharma AG, Novartis Pharmaceuticals, Washington University School of Medicine, Dana-Farber Cancer Institute
Conditions
Advanced Triple Negative Breast Cancer (TNBC) With High TAMsBone MetastasesBreast CancerCancer of BreastDifferent types of advanced cancerEndometrial CarcinomaGCCTSGCTS
Phase 1
A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
TerminatedNCT00757757
Start: 2008-09-30End: 2009-08-31Updated: 2020-12-19
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
CompletedNCT02807844
Start: 2016-06-29End: 2020-06-04Updated: 2021-08-11
MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
WithdrawnNCT03285607
Start: 2018-09-30End: 2021-02-28Updated: 2018-08-16
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
CompletedNCT03455764
Start: 2018-09-10End: 2023-09-05Updated: 2024-07-31
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
TerminatedNCT03742349
Start: 2019-01-31End: 2023-02-06Updated: 2025-05-18
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments
Active, not recruitingCTIS2023-508841-42-00
Start: 2019-10-30Target: 75Updated: 2025-10-28
Phase 2
MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)
CompletedNCT01643850
Start: 2012-04-23End: 2018-12-21Updated: 2021-01-05
Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
CompletedNCT02435680
Start: 2015-08-10End: 2020-03-23Updated: 2021-06-21